HC Wainwright & Co. Reiterates Buy on TRX Gold, Maintains $1.1 Price Target
HC Wainwright & Co. analyst Heiko Ihle reiterates TRX Gold (AMEX:TRX) with a Buy and maintains $1.1 price target.
Needham Reiterates Buy on Airbnb, Maintains $155 Price Target
Needham analyst Bernie McTernan reiterates Airbnb (NASDAQ:ABNB) with a Buy and maintains $155 price target.
JonesTrading Initiates Coverage On Trevi Therapeutics with Buy Rating, Announces Price Target of $7
JonesTrading analyst Sean Kim initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Buy rating and announces Price Target of $7.
JonesTrading Initiates Coverage On Durect with Buy Rating, Announces Price Target of $37
JonesTrading analyst Sean Kim initiates coverage on Durect (NASDAQ:DRRX) with a Buy rating and announces Price Target of $37.
Cantor Fitzgerald Initiates Coverage On Cipher Mining with Overweight Rating, Announces Price Target of $3
Cantor Fitzgerald analyst Josh Siegler initiates coverage on Cipher Mining (NASDAQ:CIFR) with a Overweight rating and announces Price Target of $3.
BMO Capital Downgrades Precision BioSciences to Market Perform, Lowers Price Target to $4
BMO Capital analyst Kostas Biliouris downgrades Precision BioSciences (NASDAQ:DTIL) from Outperform to Market Perform and lowers the price target from $7 to $4.
JP Morgan Downgrades Crestwood Equity Partners to Neutral, Lowers Price Target to $28
JP Morgan analyst Jeremy Tonet downgrades Crestwood Equity Partners (NYSE:CEQP) from Overweight to Neutral and lowers the price target from $31 to $28.
Jefferies Downgrades Provention Bio to Hold, Announces $25 Price Target
Jefferies analyst Chris Howerton downgrades Provention Bio (NASDAQ:PRVB) from Buy to Hold and announces $25 price target.
Keefe, Bruyette & Woods Upgrades Unum Gr to Outperform, Raises Price Target to $52
Keefe, Bruyette & Woods analyst Ryan Krueger upgrades Unum Gr (NYSE:UNM) from Market Perform to Outperform and raises the price target from $49 to $52.
JP Morgan Upgrades MPLX to Overweight, Raises Price Target to $41
JP Morgan analyst Jeremy Tonet upgrades MPLX (NYSE:MPLX) from Neutral to Overweight and raises the price target from $37 to $41.